Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering

Jun 28, 2024•over 1 year ago

Contract Type

partnership

BostonBiotechnology

Description

Elicio Therapeutics has announced the pricing of an approximately $11.5 million underwritten public offering of its common stock and accompanying common warrants. The offering is expected to close on or about July 1, 2024.

Company Information

Company

Elicio Therapeutics

Location

ONE KENDALL SQUARE

Boston, Massachusetts, United States

About

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (“AMP”) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.

Related People

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months